他汀使用与HIV感染者衰弱轨迹改善相关
这项在意大利Modena HIV代谢门诊开展的观察性纵向研究纳入3444名HIV感染者,比较使用他汀进行心血管预防者与未使用者的衰弱指数轨迹。校正模型显示他汀使用与衰弱指数随时间下降相关(交互项β=-2.562,95%CI -3.176至-1.987),但步速、简易体能状况量表及握力等次要结局未见关联。
要点
- 他汀使用与HIV感染者衰弱指数轨迹改善独立相关。
- 步速、简易体能状况量表及握力等次要结局未见他汀关联。
- 他汀使用者基线心血管代谢 profile 更不利,提示需校正混杂。
核心结论
- 他汀使用可能与HIV感染者衰弱轨迹改善相关,支持他汀在HIV照护中更广泛的作用。
研究设计与样本
- 观察性纵向研究,纳入意大利Modena HIV代谢门诊无基线他汀使用且至少三次衰弱指数评估的HIV感染者3444人(69%男性,中位年龄44.7岁)。
主要发现
- 23.1%以一级预防起始他汀,2.0%以二级预防起始他汀。
- 他汀使用者在T0时心血管代谢特征更不利。
- 校正模型中他汀使用与衰弱指数随时间下降相关(他汀×时间交互β=-2.562,95%CI -3.176至-1.987)。
- 步速、简易体能状况量表及握力等次要结局未观察到与他汀使用的关联。
关键数值与推荐
- 衰弱采用34项衰弱指数评估,因与他汀暴露直接相关而排除脂质变量以减少碰撞偏倚。
- 他汀使用者与非使用者按随访时长匹配,T0定义为起始他汀的时间。
临床怎么用
- 对HIV感染者进行心血管预防性他汀处方时,可关注其对衰弱轨迹的潜在获益。
- 衰弱评估可作为HIV老年照护中监测功能变化的有用工具。
局限性
- 原文未报告局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Statins have pleiotropic properties beyond LDL cholesterol reduction, including anti-inflammatory and immunomodulatory effects that may influence biological aging and frailty. The primary objective was to compare frailty trajectories in people with HIV using statins for cardiovascular prevention with those not using statins. Secondary objectives included differences in walking speed, short physical performance battery, and hand grip strength. This observational longitudinal study included people with HIV from the Modena HIV Metabolic Clinic (Italy) with no prior statin use at baseline and at least three frailty index (FI) assessments. Baseline was the first visit with a FI assessment; follow-up was the last visit. Statin users and non-users were matched for follow-up duration. Time 0 (T0) was defined as statin initiation. Frailty was assessed with a 34-item FI. To minimize collider bias, lipid variables were excluded from the FI due to their direct relationship with statin exposure. Frailty trajectories and secondary outcomes were analyzed using linear mixed models. Beta-estimates were multiplied by 100 to improve readability. Among 3,444 people with HIV (69% men; median age 44.7 years), 23.1% initiated statins for primary prevention and 2.0% for secondary prevention. Statin users had a more unfavorable cardiometabolic profile at T0. In adjusted models, statin use was associated with a reduction in FI over time (statin*time interaction β=-2.562, 95%-CI -3.176,-1.987). No associations were observed with secondary outcomes. Statins may improve frailty trajectories, mitigate aging-related decline and preserve physical function in people with HIV, supporting a broader role for statins in HIV care.
引用
- Milic J, Carobbio A, Menozzi M, et al. Statin use is associated with improved frailty trajectories in people with HIV. J Gerontol A Biol Sci Med Sci. 2026. PMID: 42717432. doi:10.1093/gerona/glag223
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。